Dee Rapposelli

Researchers evaluated the effects of poor sleep and low heart rate variability on the odds of metabolic syndrome.

A phase 2 clinical trial examined the efficacy of treating painful diabetic neuropathy (PDN) with filorexant, an orexin receptor antagonist.